Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 821 of 5804
-
Experimental combo shows promise for Tough-to-Treat cancers
Disease control OngoingThis is a multi-cohort single arm phase II/screening trial of the combination of a fusion protein that binds EphrinB2 and blocks interaction with cell surface EphB receptors (sEphB4-HSA) in combination with an anti-PD1 antibody (MK-7435 / Pembrolizumab) for treatment of patients …
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New immunotherapy shows promise against multiple advanced cancers
Disease control OngoingThe Primary purpose of this study is to identify the recommended Phase 2 dose \[RP2D(s)\] for JNJ-63723283 in Part 1, to assess the anti-tumor activity of JNJ-63723283 at the RP2D(s) in participants with selected advanced cancers including non-small-cell lung cancer (NSCLC), mela…
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New cocktail of drugs takes on Hard-to-Treat prostate cancer
Disease control OngoingThe purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Coh…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Immune cells and drugs injected directly into brain tumor in new trial
Disease control OngoingPhase I/II clinical trial on the per-operative intra-tumoral administration of myeloid dendritic cells plus ipilimumab and nivolumab, followed by repeated intracavitary administration of ipilimumab and nivolumab plus intravenous administration of nivolumab in patients with recurr…
Phase: PHASE1, PHASE2 • Sponsor: Universitair Ziekenhuis Brussel • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug cocktail shows promise for recurrent ovarian cancer
Disease control OngoingThis research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Common heart drug may shield eyes of type 1 diabetes patients
Disease control OngoingThe purpose of this study is to evaluate the potential benefits of 145 mg of daily fenofibrate in adults with type 1 diabetes mellitus and pre-existing non-proliferative diabetic retinopathy.
Phase: PHASE3 • Sponsor: University of Sydney • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for tough breast cancer: drug cocktail targets resistant tumors
Disease control CompletedThis phase II trial studies how well panitumumab, carboplatin and paclitaxel work in treating patients with newly diagnosed triple negative breast cancer that is limited to the breast and possibly to the nearby lymph nodes (locally advanced). This treatment study is linked to NCI…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New device aims to fix leaky heart valves without stopping the heart
Disease control OngoingThe objective of this trial is to assess the safety and effectiveness of the study device in subjects with degenerative mitral valve disease receiving a mitral valve repair without cardiopulmonary bypass (treatment group) when compared to subjects receiving mitral valve repair us…
Phase: NA • Sponsor: NeoChord • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for kids with rare immune disorder: international trial tests drug cocktails
Disease control OngoingThe LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).
Phase: PHASE2, PHASE3 • Sponsor: North American Consortium for Histiocytosis • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Could a cholesterol drug boost reading skills in kids with NF1?
Disease control OngoingNeurofibromatosis Type 1 (NF1) is a common genetic disorder that is associated with a four times greater risk of learning disabilities, including reading disabilities, and a deficiency of neurofibromin - a protein important in a signaling pathway that regulates learning and memor…
Phase: PHASE2 • Sponsor: Vanderbilt University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo vaccine for babies shows promise in large trial
⭐️ VACCINE ⭐️ CompletedThe purpose of this study is to: * (cohort 1) evaluate safety and immunogenicity (Haemophilus influenzae type b, Hib) of BK1310. * (cohort 2) evaluate efficacy and safety of BK1310 using ActHIB® and Tetrabik as a control in healthy infants.
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:08 UTC
-
Immunotherapy combo shows promise in shrinking oral tumors before surgery
Disease control OngoingThis research study is studying nivolumab, an investigational drug, in combination with ipilimumab, also an investigational drug, as a possible treatment for Squamous Cell Carcinoma of the oral cavity. The following drugs are involved in this study: * Nivolumab (Opdivo™) * Ipil…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Cold virus engineered to attack pancreatic cancer shows promise in early trial
Disease control CompletedThe purpose of this study is to see if LOAd703 (an oncolytic adenovirus) can be safely given to patients with pancreatic cancer. The study will also evaluate whether or not intratumoral injection of LOAd703 will support current standard of care treatment to reduce the size of the…
Phase: PHASE1, PHASE2 • Sponsor: Lokon Pharma AB • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New study uses MRI to catch pancreatic cancer early in High-Risk families
Diagnosis Recruiting nowThe main goal of this study is to screen and detect pancreatic cancer and precursor lesions in individuals with a strong family history or genetic predisposition to pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI/MRCP) will be utilized to …
Sponsor: Nuvance Health • Aim: Diagnosis
Last updated Jun 27, 2026 12:06 UTC
-
Brittle bone breakthrough? new drug combo aims to cut fractures
Disease control CompletedOsteogenesis imperfecta (OI) is an inherited skeletal disorder characterised by increased risk of fragility fractures. Bisphosphonates are frequently prescribed for adult patients with OI with the aim of preventing fractures but the evidence base for efficacy is poor. Recent evid…
Phase: PHASE4 • Sponsor: University of Edinburgh • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Can taking drug breaks work as well as continuous treatment for melanoma?
Disease control Recruiting nowThe purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if the two ways of giving this type of tre…
Phase: PHASE3 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Promising new pill shrinks liver fat in NASH patients
Disease control CompletedThe primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in participants with biopsy-proven Non-alcoholic Steatohepatitis (NASH).
Phase: PHASE2 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Ebola vaccine booster study aims to strengthen protection for frontline workers
Prevention CompletedBackground: The Ebola virus causes a severe disease that can be fatal. The usual incubation period to illness after being exposed is 2 to 21 days. There are only limited treatments currently available for Ebola infection. A vaccine to prevent infection either before or after exp…
Phase: PHASE2 • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
New hope for myeloma: experimental drug iberdomide tested in combo therapy
Disease control OngoingThis is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220…
Phase: PHASE1, PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New combo therapy shows promise for tough pancreatic cancers
Disease control CompletedThis is a prospective, randomized phase II trial. The aim of this study is to assess the efficacy of two therapeutics strategies. Patients with borderline-resectable pancreatic cancer (BRPC) will be randomly in two arms : neoadjuvant mFolfirinox followed with or without preoperat…
Phase: PHASE2 • Sponsor: Institut de Cancérologie de Lorraine • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC